July 8 (Reuters) - Emergent BioSolutions Inc:
* MOUNT SINAI HEALTH SYSTEM, EMERGENT BIOSOLUTIONS, AND IMMUNOTEK BIO CENTERS FORM COLLABORATION TO DEVELOP EMERGENT’S COVID-19 HYPERIMMUNE GLOBULIN (COVID-HIG) PRODUCT CANDIDATE WITH U.S. DEPARTMENT OF DEFENSE FUNDING
* EMERGENT BIOSOLUTIONS - IMMUNOTEK TO EXTEND OPERATING LICENSE, PROVIDE TRAINING TO MOUNT SINAI TO ESTABLISH ONSITE PLASMA COLLECTION
* EMERGENT BIOSOLUTIONS INC - COLLABORATION HAS FUNDING OF $34.6 MILLION FROM U.S. DEPARTMENT OF DEFENSE
* EMERGENT BIOSOLUTIONS - WILL EVALUATE COVID-HIG IN A POST-EXPOSURE PROPHYLAXIS STUDY IN INDIVIDUALS AT HIGH RISK OF EXPOSURE TO COVID-19
* EMERGENT BIOSOLUTIONS - WILL SUPPORT IMMUNOTEK, MOUNT SINAI IN OTHER REGULATORY, COMPLIANCE EFFORTS RELATED TO PLASMA COLLECTION & SUPPLY Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.